1.A Case of Gastric Bezoar Formed by Ingestion of Gypsum, and it was Treated Endoscopically Using Electrohydraulic Lithotripsy.
Jong Kwan PARK ; Min Su KIM ; Young Gyun KIM ; Won Na SUH ; Tae Il KIM ; Hyojin PARK
Korean Journal of Gastrointestinal Endoscopy 2005;31(5):328-333
Gastric bezoars are collection of indigestible material in the stomach, and these can be classified into five broad categories: phytobezoar, trichobezoar, pharmacobezoar, lactobezoar and miscellaneous materials such as sand, stone and concrete (gypsum). The treatment of gastric bezoars has recently changed from surgical management to such nonsurgical interventions as enzymatic dissolution, nasogastric suctioning and endoscopic removal by polypectomy snare and basket. Up to the present, electrohydraulic lithotripsy has been a well established method for the treatment of urinary and hepatobiliary stones. We report here on a patient who had a huge gastric bezoar that was formed by the ingestion of gypsum, and this was treated with endoscopic electrohydraulic lithotripsy.
Bezoars*
;
Calcium Sulfate*
;
Eating*
;
Endoscopy
;
Humans
;
Lithotripsy*
;
Silicon Dioxide
;
SNARE Proteins
;
Stomach
;
Suction
2.Long-term survival after intraperitoneal chemotherapy with paclitaxel-cisplatin for recurrent primary peritoneal cancer resistant to multiple lines of intravenous chemotherapy
Hyejeong HUE ; Kidong KIM ; HyoJin KIM ; Dong Hoon SUH ; Jae Hong NO ; Yong Beom KIM
Obstetrics & Gynecology Science 2019;62(4):285-289
The long-term survival of heavily pretreated patients with primary peritoneal cancer (PPC) is uncommon. Here, we report on a patient with PPC refractory to multiple lines of intravenous chemotherapy, namely, a combined regimen of paclitaxel and carboplatin, and single regimens of topotecan, docetaxel, cisplatin, and gemcitabine. However, after intraperitoneal (IP) chemotherapy with paclitaxel-cisplatin, the patient's condition improved, and she has been progression-free for more than 4 years. Interestingly, before the IP chemotherapy, the recurrences were limited to the peritoneal cavity. These results suggest that IP recurrence might be a predictor of a good response to IP chemotherapy.
Carboplatin
;
Cisplatin
;
Drug Therapy
;
Humans
;
Infusions, Parenteral
;
Neoplasm Recurrence, Local
;
Ovarian Neoplasms
;
Paclitaxel
;
Peritoneal Cavity
;
Peritoneal Neoplasms
;
Recurrence
;
Topotecan
3.Nonautoimmune congenital hyperthyroidism due to p.Asp633Glu mutation in the TSHR gene.
Won Kyoung CHO ; Moon Bae AHN ; Woori JANG ; Hyojin CHAE ; Myungshin KIM ; Byung Kyu SUH
Annals of Pediatric Endocrinology & Metabolism 2018;23(4):235-239
Most cases of congenital hyperthyroidism are autoimmune forms caused by maternal thyroid stimulating antibodies. Nonautoimmune forms of congenital hyperthyroidism caused by activating mutations of the thyrotropin receptor (TSHR) gene are rare. A woman gave birth to a boy during an emergency cesarean section at 33 weeks of gestation due to fetal tachycardia. On the 24th day of life, thyroid function tests were performed due to persistent tachycardia, and hyperthyroidism was confirmed. Auto-antibodies to TSHR, thyroid peroxidase, and thyroglobulin were not found. The patient was treated with propylthiouracil and propranolol, but hyperthyroidism was not well controlled. At 3 months of age, the patient had craniosynostosis and hydrocephalus, and underwent a ventriculoperitoneal shunt operation. Direct sequencing of the TSHR gene showed a heterozygous mutation of c.1899C>A (p.Asp633Glu) in exon 10. No mutations were discovered in any of the parents in a familial genetic study. We have reported a case of sporadic nonautoimmune congenital hyperthyroidism, by a missense mutation of the TSHR gene, for the first time in South Korea.
Cesarean Section
;
Craniosynostoses
;
Emergencies
;
Exons
;
Female
;
Germ-Line Mutation
;
Humans
;
Hydrocephalus
;
Hyperthyroidism*
;
Immunoglobulins, Thyroid-Stimulating
;
Iodide Peroxidase
;
Korea
;
Male
;
Mutation, Missense
;
Parents
;
Parturition
;
Pregnancy
;
Propranolol
;
Propylthiouracil
;
Receptors, Thyrotropin
;
Tachycardia
;
Thyroglobulin
;
Thyroid Function Tests
;
Ventriculoperitoneal Shunt
4.Clinical evaluation of a droplet digital PCR assay for detecting POLE mutations and molecular classification of endometrial cancer
Gilhyang KIM ; Song Kook LEE ; Dong Hoon SUH ; Kidong KIM ; Jae Hong NO ; Yong Beom KIM ; Hyojin KIM
Journal of Gynecologic Oncology 2022;33(2):e15-
Objective:
We evaluated droplet digital polymerase chain reaction (ddPCR) method for detecting POLE mutations in endometrial cancer (EC) and guiding its molecular classification.
Methods:
We reviewed 240 EC specimens from our hospital database. A ddPCR assay was used to identify POLE mutations at 5 known hotspots (P286R, S297F, V411L, A456P, and S459F). Expressions of p53 and mismatch repair proteins were identified using immunohistochemistry.
Results:
The ddPCR assay identified POLEmutations in 10.8% of patients. The most common mutation was V411L (61.54%), followed by P286R (23.07%), S459F (7.69%), S297F (3.85%), and A456P (3.85%). Eight/one cases had positive ddPCR but negative Sanger sequencingext-generation sequencing, respectively. Molecular classification revealed p53-mutated subtype as significantly more common for tumors with a high International Federation of Gynecology and Obstetrics (FIGO) grade, deep myometrial invasion, lymphovascular space invasion, advanced stage, and high/advanced risk groups; the POLE mutated group was more frequent in the low stage and low/intermediate risk group. Survival analyses revealed the poorest outcomes for p53-mutated EC, while mismatch repair-deficient and no specific molecular profile ECs had similar progression-free survival (PFS) outcomes, and POLE -mutated ECs had the best PFS outcome (p<0.001). When only intermediate, high-intermediate, and high-risk groups were analyzed for subgroups, molecular classification still showed differences both in PFS (p=0.003) and overall survival (p=0.017).
Conclusion
Hotspot POLE mutations can be detected using the ddPCR assay. We suggest simultaneously evaluating POLE mutation status using ddPCR and p53/mismatch repair protein expressions using immunohistochemistry, which can rapidly and accurately determine the molecular subtype of EC.
5.Clinicopathologic and protein markers distinguishing the “polymerase epsilon exonuclease” from the “copy number low” subtype of endometrial cancer
Kidong KIM ; Suhyun HWANGBO ; Hyojin KIM ; Yong Beom KIM ; Jae Hong NO ; Dong Hoon x SUH ; Taesung PARK
Journal of Gynecologic Oncology 2022;33(3):e27-
Objective:
The need to perform genetic sequencing to diagnose the polymerase epsilon exonuclease (POLE) subtype of endometrial cancer (EC) hinders the adoption of molecular classification. We investigated clinicopathologic and protein markers that distinguish the POLE from the copy number (CN)-low subtype in EC.
Methods:
Ninety-one samples (15 POLE, 76 CN-low) were selected from The Cancer Genome Atlas EC dataset. Clinicopathologic and normalized reverse phase protein array expression data were analyzed for associations with the subtypes. A logistic model including selected markers was constructed by stepwise selection using area under the curve (AUC) from 5-fold cross-validation (CV). The selected markers were validated using immunohistochemistry (IHC) in a separate cohort.
Results:
Body mass index (BMI) and tumor grade were significantly associated with the POLE subtype. With BMI and tumor grade as covariates, 5 proteins were associated with the EC subtypes. The stepwise selection method identified BMI, cyclin B1, caspase 8, and X-box binding protein 1 (XBP1) as markers distinguishing the POLE from the CN-low subtype. The mean of CV AUC, sensitivity, specificity, and balanced accuracy of the selected model were 0.97, 0.91, 0.87, and 0.89, respectively. IHC validation showed that cyclin B1 expression was significantly higher in the POLE than in the CN-low subtype and receiver operating characteristic curve of cyclin B1 expression in IHC revealed AUC of 0.683.
Conclusion
BMI and expression of cyclin B1, caspase 8, and XBP1 are candidate markers distinguishing the POLE from the CN-low subtype. Cyclin B1 IHC may replace POLE sequencing in molecular classification of EC.
6.Prenatal Diagnosis of Congenital Lipoid Adrenal Hyperplasia (CLAH) by Molecular Genetic Testing in Korean Siblings.
Hyun Sun KO ; Seungok LEE ; Hyojin CHAE ; Sae Kyung CHOI ; Myungshin KIM ; In Yang PARK ; Byung Kyu SUH ; Jong Chul SHIN
Yonsei Medical Journal 2011;52(6):1035-1038
Congenital lipoid adrenal hyperplasia (CLAH) is caused by mutations to the steroidogenic acute regulatory protein (StAR) gene associated with the inability to synthesize all adrenal and gonadal steroids. Inadequate treatment in an infant with this condition may result in sudden death from an adrenal crisis. We report a case in which CLAH developed in Korean siblings; the second child was prenatally diagnosed because the first child was affected and low maternal serum estriol was detected in a prenatal screening test. To our knowledge, this is the first prenatal diagnosis of the Q258X StAR mutation, which is the only consistent genetic cluster identified to date in Japanese and Korean populations.
46, XY Disorders of Sex Development/*diagnosis/*genetics
;
Adrenal Hyperplasia, Congenital/*diagnosis/*genetics
;
Adult
;
Asian Continental Ancestry Group
;
Female
;
Genetic Testing/*methods
;
Humans
;
Korea
;
Prenatal Diagnosis/*methods
7.A Case of Pseudohypoparathyroidism Type Ib Caused by Aberrant Methylation in the GNAS Complex Locus.
Sung Jin JO ; Eunhee HAN ; Woori JANG ; Hyojin CHAE ; Yonggoo KIM ; Gun Dong LEE ; Won Kyoung CHO ; Byung Kyu SUH ; Myungshin KIM
Laboratory Medicine Online 2017;7(2):83-87
Pseudohypoparathyroidism (PHP) is a rare disorder caused by genetic and epigenetic aberrations in the GNAS complex locus resulting in impaired expression of stimulatory G protein (Gsα). PHP type Ib (PHP-Ib) is characterized by hypocalcemia and hyperphosphatemia due to renal resistance to the parathyroid hormone, and is distinguished from PHP-Ia by the absence of osteodystrophic features. An 11-yr-old boy presented with poor oral intake and cramping lower limb pain after physical activity. Laboratory studies revealed hypocalcemia, hyperphosphatemia, and increased parathyroid hormone levels. The GNAS complex locus was evaluated using the methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) assay. Gain of methylation in the NESP55 domain and loss of methylation in the antisense (AS) transcript, XL, and A/B domains in the maternal allele were observed. Consequently, we present a case of PHP-Ib diagnosed using MS-MLPA.
Alleles
;
Epigenomics
;
GTP-Binding Proteins
;
Humans
;
Hyperphosphatemia
;
Hypocalcemia
;
Lower Extremity
;
Male
;
Methylation*
;
Motor Activity
;
Multiplex Polymerase Chain Reaction
;
Muscle Cramp
;
Parathyroid Hormone
;
Pseudohypoparathyroidism*
8.Estrogen-induced acute pancreatitis: A case report and literature review.
Dajeong SEO ; Hyojin SUH ; Jun Kyu LEE ; Dong Kee JANG ; Ha Yan KWON ; Chae Hyeong LEE ; Sang Ho YOON ; Ju Won ROH ; Hyun Soo PARK
Obstetrics & Gynecology Science 2017;60(5):485-489
Estrogens are commonly used in gynecologic area, such as oral contraception, hormone replacement therapy, and in vitro fertilization-embryo transfer. Although estrogen is a common cause of acute drug-induced pancreatitis, there has been paucity of report in Korea. Clinical course of estrogen-induced acute pancreatitis is usually mild to moderate, but fetal case can occur. In addition, there can be a latency from the first administration to the symptom. Therefore, physicians should consider the possibility of the disease when a woman taking estrogen or previous history of taking estrogen presents with acute abdominal pain. Here, we report a case of estrogen-induced acute pancreatitis that occurred during the preparation for embryo transfer.
Abdominal Pain
;
Contraception
;
Embryo Transfer
;
Estrogens
;
Female
;
Hormone Replacement Therapy
;
Humans
;
In Vitro Techniques
;
Korea
;
Pancreatitis*
9.Two Cases of Shwachman-Diamond Syndrome in Adolescents Confirmed by Genetic Analysis.
Won Kyoung CHO ; In Ah JUNG ; Jiyeon KIM ; Hyojin CHAE ; Myungshin KIM ; Nack Gyun CHUNG ; Byung Kyu SUH
Annals of Laboratory Medicine 2015;35(2):269-271
No abstract available.
Adolescent
;
Base Sequence
;
Bone Marrow Diseases/*diagnosis/diagnostic imaging/genetics
;
DNA Mutational Analysis
;
Exocrine Pancreatic Insufficiency/*diagnosis/diagnostic imaging/genetics
;
Humans
;
Lipomatosis/*diagnosis/diagnostic imaging/genetics
;
Magnetic Resonance Imaging
;
Male
;
Mutation
;
Proteins/genetics
;
Tomography, X-Ray Computed
10.Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non–Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
Hyojin KIM ; Hyun Jung KWON ; Eun Sun KIM ; Soohyeon KWON ; Kyoung Jin SUH ; Se Hyun KIM ; Yu Jung KIM ; Jong Seok LEE ; Jin-Haeng CHUNG
Cancer Research and Treatment 2022;54(2):424-433
Purpose:
Since tumor mutational burden (TMB) and gene expression profiling (GEP) have complementary effects, they may have improved predictive power when used in combination. Here, we investigated the ability of TMB and GEP to predict the immunotherapy response in patients with non–small cell lung cancer (NSCLC) and assessed if this combination can improve predictive power compared to that when used individually.
Materials and Methods:
This retrospective cohort study included 30 patients with NSCLC who received immune checkpoint inhibitors (ICI) therapy at the Seoul National University Bundang Hospital. programmed cell death-ligand-1 (PD-L1) protein expression was assessed using immunohistochemistry, and TMB was measured by targeted deep sequencing. Gene expression was determined using NanoString nCounter analysis for the PanCancer IO360 panel, and enrichment analysis were performed.
Results:
Eleven patients (36.7%) showed a durable clinical benefit (DCB), whereas 19 (63.3%) showed no durable benefit (NDB). TMB and enrichment scores (ES) showed significant differences between the DCB and NDB groups (p=0.044 and p=0.017, respectively); however, no significant correlations were observed among TMB, ES, and PD-L1. ES was the best single biomarker for predicting DCB (area under the curve [AUC], 0.794), followed by TMB (AUC, 0.679) and PD-L1 (AUC, 0.622). TMB and ES showed the highest AUC (0.837) among other combinations (AUC [TMB and PD-L1], 0.777; AUC [PD-L1 and ES], 0.763) and was similar to that of all biomarkers used together (0.832).
Conclusion
The combination of TMB and ES may be an effective predictive tool to identify patients with NSCLC patients who would possibly benefit from ICI therapies.